300158 振东制药
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入782,130-17.79%3,626,0163,728,5555,093,7764,847,833
减:营业总成本795,148-18.68%3,777,4323,922,1925,009,6384,589,834
    其中:营业成本434,919-13.77%1,799,4161,889,8422,054,4491,830,827
               财务费用(449)-53.83%(9,566)9,98814,35618,546
               资产减值损失1,63120,829.54%(36,242)(5,253)(16,937)6,298
公允价值变动收益2,649-33.00%1,95811,5918326
投资收益16,88972.64%43,08254,4592,953,33313,979
    其中:对联营企业和合营企业的投资收益------------
营业利润32,290342.07%(29,983)(5,920)3,121,565326,221
利润总额30,993316.46%(37,693)(5,280)3,116,118322,860
减:所得税费用8,6463.62%10,17751,718506,49369,286
净利润22,347-2,577.33%(47,869)(56,999)2,609,625253,574
减:非控股权益(754)48.70%(3,885)(5,709)(7,804)(8,453)
股东净利润23,102-5,952.52%(43,984)(51,290)2,617,430262,027

市场价值指针
每股收益 (元) *0.023-5,725.00%-0.043-0.0502.5470.255
每股派息 (元) *--------2.8000.070
每股净资产 (元) *4.981-2.59%5.0405.1147.8635.494
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容